Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:AMGN

Amgen Q3 2026 Earnings Date & Estimates

Amgen logo
$441.30 -5.98 (-1.34%)
As of 01:27 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Amgen is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Amgen in Q3 2026

Amgen is expected to post earnings of $5.78 per share on revenue of $10.07 billion. In the same quarter a year earlier Amgen reported $5.64 per share on revenue of $9.56 billion. Amgen last reported on August 4, 2026, posting $6.29 per share and beating the $5.62 consensus estimate. Amgen has beaten the consensus EPS estimate in 8 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$5.78
Expected Revenue
$10.07 billion
Prior-Year EPS
$5.64
Prior-Year Revenue
$9.56 billion
Expected EPS Growth
+2.5%
Expected Revenue Growth
+5.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$6.29 (Beat by +$0.67)
Last Quarter Revenue
$10.05 billion
EPS Beat Rate
8 of last 8 quarters

Prepare for the Q3 2026 Call

Amgen Q3 2026 Earnings FAQ

Amgen (NASDAQ:AMGN) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Amgen's Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Amgen to post earnings of $5.78 per share for Q3 2026.

The consensus revenue estimate for Amgen is $10.07 billion for Q3 2026.

Amgen Earnings Headlines

Amgen’s Bemarituzumab Trial Reaches Phase 3 Finish Line in Gastric Cancer
 |  tipranks.comhttps://www.tipranks.com/news/company-announcements/amgens-bemarituzumab-trial-reaches-phase-3-finish-line-in-gastric-cancer?utm_source=marketbeat.com&utm_medium=referral
At Amgen, Sustainability Is A Companywide Commitment
 |  finance.yahoo.comhttps://finance.yahoo.com/m/35ed4ecb-1fa2-30c4-b716-8456328776e0/at-amgen%2C-sustainability-is-a.html
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
October 23 at 1:00 AM  |  Stansberry Research (Ad)
Amgen Reaches a New 52-Week High at $447.28, Up 55% From October Lows
October 22 at 8:54 PM  |  247wallst.comhttps://247wallst.com/cards/amgen-closed-at-447-28-a-new-52-week-high-roughly-55-abo-amgn-price-extreme-01m5k03zvb0d8kd7eaz87fnky0
Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains
October 22 at 8:54 PM  |  marketwatch.comhttps://www.marketwatch.com/data-news/amgen-inc-stock-underperforms-thursday-when-compared-to-competitors-despite-daily-gains-8d163645-653a4564cc09
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
October 22 at 5:55 PM  |  fool.comhttps://www.fool.com/coverage/better-buy/2026/10/22/amgen-vs-eli-lilly-does-the-glp-1-mania-make-lly-stock-a-better-buy-in-2026/
See More Amgen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Amgen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amgen and other key companies, straight to your email.

About Amgen

Amgen (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California. The company serves patients and healthcare providers in the United States and international markets through its research, manufacturing and commercial operations. Amgen is led by Chairman and Chief Executive Officer Robert A. Bradway.

View Amgen Profile
Earnings Tools